Cataract future or investigational therapies

Jump to navigation Jump to search

Cataract Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cataract from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cataract future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cataract future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cataract future or investigational therapies

CDC on Cataract future or investigational therapies

Cataract future or investigational therapies in the news

Blogs on Cataract future or investigational therapies

Directions to Hospitals Treating Cataract

Risk calculators and risk factors for Cataract future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Future or Investigational Therapies

Although statins are known for their ability to lower lipids, they are also believed to have antioxidant qualities. It is believed that oxidative stress plays a role in the development of nuclear cataracts, which are the most common type of age-related cataract. To explore the relationship between nuclear cataracts and statin use, a group of researchers took a group of 1299 patients who were at risk of developing nuclear cataracts and gave some of them statins. Their results suggest that statin use in a general population may be associated with a lower risk of developing nuclear cataract disease. [1]

Research is scant and mixed but weakly positive for the nutrients lutein and zeaxanthin[2][3][4][5]. Bilberry extract shows promise in rat models [6][7] and in clinical studies.[8]

References

  1. Klein, Barbara. "Statin Use and Incident Nuclear Cataract". Journal of the American Medical Association. 295 (23): 2752–2758. Unknown parameter |coauthors= ignored (help)
  2. Nutrition. 2003 Jan;19(1):21 Lutein, but not alpha-tocopherol, supplementation improves visual function in patients with age-related cataracts: a 2-y double-blind, placebo-controlled pilot study
  3. Invest Ophthalmol Vis Sci. 2006 Sep;47(9):3783-6. Lutein and zeaxanthin and the risk of cataract: the Melbourne visual impairment project
  4. Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2329-35. Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: the POLA Study
  5. J Am Coll Nutr. 2004 Dec;23(6 Suppl):567S-587S Lutein and zeaxanthin and their potential roles in disease prevention
  6. Dietary supplementation with bilberry extract prevents macular degeneration and cataracts in senesce-accelerated OXYS rats Adv Gerontol. 2005;16:76-9
  7. Yamakoshi J, et al. J Agric Food Chem. 2002 Aug 14;50(17):4983-8.
  8. Ann Ottalmol Clin Ocul, 1989